Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: a Mendelian randomization study

Mark Gormley[1,2,3]*, James Yarmolinsky[1,3], Tom Dudding[1,2,3], Kimberley Burrows[1,3], Richard M Martin[1,3,4], Steven Thomas[2,4], Jessica Tyrrell[5], Paul Brennan[6], Miranda Pring[2], Stefania Boccia[7,8], Andrew F Olshan[9], Brenda Diergaarde[10], Rayjean J. Hung[11,12], Geoffrey Liu[12,13], Danny Legge[14], Eloiza H Tajara[15], Patricia Severino [16], Martin Lacko[17], Andrew R Ness[4], George Davey Smith[1,3], Emma E Vincent[1,3,14&], Rebecca C Richmond[1,3&]

[1] MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

[2] Bristol Dental Hospital and School, University of Bristol, Bristol, UK.

[3] Department of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

[4] National Institute for Health Research Bristol Biomedical Research Centre at the University Hospitals Bristol and Weston NHS Foundation Trust, University of Bristol, Bristol, UK.

[5] University of Exeter Medical School, RILD Building, RD&E Hospital, Exeter, UK.

[6] Genetic Epidemiology Group, World Health Organization, International Agency for Research on Cancer, Lyon, France.

[7] Sezione di Igiene, Istituto di Sanità Pubblica, Università Cattolica del Sacro Cuore, Roma, Italy.

[8] Department of Woman and Child Health and Public Health, Public Health Area, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.

[9] Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, US.

[10] Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, and UPMC Hillman Cancer Center, Pittsburgh, US.

[11] Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada.

[12] Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.

[13] Princess Margaret Cancer Centre, Toronto Canada.

[14] School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.

[15] School of Medicine of São José do Rio Preto, São Paulo, Brazil.

[16] Albert Einstein Research and Education Institute, Hospital Israelita Albert Einstein, São Paulo, Brazil.

[17] Department of Otorhinolaryngology and Head and Neck Surgery, Research Institute GROW, Maastricht University Medical Center, Maastricht, The Netherlands.

Corresponding author

* Email: mark.gormley@bristol.ac.uk

Author contributions

[&] These authors also contributed equally to this work.

E.E.V. and R.C.R. are joint senior authors. M.G., R.C.R. and E.E.V. conceived the study and M.G. carried out data curation and formal analysis. K.B. performed the GWAS of head and neck cancer in UK Biobank. Head and neck cancer summary genetic data was obtained through multiple collaborations from studies lead and curated by A.R.N., S.T., A.F.O., B.D., R.J.H., G.L., M.L., E.T., S.B. and P.B. Expert guidance on MR methodology was provided by R.C.R., J.Y., G.D.S. and R.M.M., R.C.R., G.D.S, J.T., S.T., P.B., R.M.M. and A.R.N. provided expertise on both observational and genetic epidemiological methodology and analysis. The initial manuscript was drafted by M.G., R.C.R. and E.E.V. All authors (M.G., J.Y., T.D., K.B., R.M.M., S.T., J.T., A.R.N., P.B., M.P., S.B., A.F.O., B.D, R.J.H., G.L., D.L., E.H.T., P.S., M.L., A.R.N., G.D.S., E.E.V. and R.C.R.) contributed to the interpretation of the results, editing and critical revision of the manuscript. M.G.'s PhD supervisory team includes R.C.R., E.E.V., J.T., A.R.N and G.D.S.

57 **Abbreviations:** HNSCC, head and neck squamous cell carcinoma; OC, oral cancer; OPC,
58 oropharyngeal cancer; HPV, human papilloma virus; MR, Mendelian randomization; GWAS,
59 genome-wide association study; SNP, single nucleotide polymorphism; PCA, principal
60 component analysis; NOME, no measurement error; SIMEX, simulation extrapolation; MR-
61 PRESSO, Mendelian Randomization Pleiotropy RESidual Sum and Outlier; GAME-ON, Genetic
62 Associations and Mechanisms in Oncology; HMGCR, 3-hydroxy-3-methylglutaryl-CoA
63 reductase; NPC1L1, NPC1 like intracellular cholesterol transporter 1; CETP, cholesteryl ester
64 transfer protein; PCSK9, proprotein convertase subtilisin/kexin type 9; LDLR, low-density
65 lipoprotein receptor; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density
66 lipoprotein cholesterol; LD, linkage disequilibrium; OR, odds ratio; se, standard error; IVW,
67 inverse variance weighted; CI, confidence intervals; P, *p*-value.

68

69

70

71

72

73

74

75

Abstract

Introduction

Head and neck squamous cell carcinoma (HNSCC), which includes cancers of the oral cavity and oropharynx, is a cause of substantial global morbidity and mortality. Strategies to reduce disease burden include discovery of novel therapies and repurposing of existing drugs. Statins are commonly prescribed for lowering circulating cholesterol by inhibiting HMG-CoA reductase (HMGCR). Results from some observational studies suggest that statin use may reduce HNSCC risk. We appraised the relationship of genetically-proxied cholesterol-lowering drug targets and other circulating lipid traits with oral (OC) and oropharyngeal (OPC) cancer risk.

Methods and findings

We conducted two-sample Mendelian randomization (MR). For the primary analysis, germline genetic variants in *HMGCR*, *NPC1L1*, *CETP, PCSK9* and *LDLR* were used to proxy the effect of low-density lipoprotein cholesterol (LDL-C) lowering therapies. In secondary analyses, variants were used to proxy circulating levels of other lipid traits in a genome-wide association study (GWAS) meta-analysis of 188,578 individuals. Both primary and secondary analyses aimed to estimate the downstream causal effect of cholesterol lowering therapies on OC and OPC risk.

The second sample for MR was taken from a GWAS of 6,034 OC and OPC cases and 6,585 controls (GAME-ON). Analyses were replicated in UK Biobank, using 839 OC and OPC

cases and 372,016 controls and the results of the GAME-ON and UK Biobank analyses combined in a fixed-effects meta-analysis.

We found limited evidence of a causal effect of genetically-proxied LDL-C lowering using HMGCR, NPC1L1, CETP or other circulating lipid traits on either OC or OPC risk. Genetically-proxied PCSK9 inhibition equivalent to a 1 mmol/L (38.7 mg/dL) reduction in LDL-C was associated with an increased risk of OC and OPC combined (OR 1.8 95%CI 1.2, 2.8, p= 9.31 $x10^{-05}$), with good concordance between GAME-ON and UK Biobank (I^2= 22%). Effects for PCSK9 appeared stronger in relation to OPC (OR 2.6 95%CI 1.4, 4.9) than OC (OR 1.4 95%CI 0.8, 2.4). LDLR variants, resulting in genetically-proxied reduction in LDL-C equivalent to a 1 mmol/L (38.7 mg/dL), reduced the risk of OC and OPC combined (OR 0.7, 95%CI 0.5, 1.0, p= 0.006). A series of pleiotropy-robust and outlier detection methods showed that pleiotropy did not bias our findings.

Conclusion

We found limited evidence for a role of cholesterol-lowering in OC and OPC risk, suggesting previous observational results may have been confounded. There was some evidence that genetically-proxied inhibition of PCSK9 increased risk, while lipid-lowering variants in LDLR, reduced risk of combined OC and OPC. This result suggests that the mechanisms of action of PCSK9 on OC and OPC risk may be independent of its cholesterol lowering effects, but further replication of this finding is required.

Author summary

Why was this study done?

- To determine if genetically-proxied cholesterol-lowering drugs (such as statins which target HMGCR) reduce oral and oropharyngeal cancer risk.
- To determine if genetically-proxied circulating lipid traits (e.g. low-density lipoprotein cholesterol) have a causal effect on oral and oropharyngeal cancer risk.

What did the researchers do and find?

- There was little evidence that genetically-proxied inhibition of HMGCR (target of statins), NPC1L1 (target of ezetimibe) and CETP (target of CETP inhibitors) influences oral or oropharyngeal cancer risk.
- There was little evidence of an effect of circulating lipid traits on oral or oropharyngeal cancer risk.
- There was some evidence that genetically-proxied inhibition of PCSK9 increases, while lipid-lowering variants in LDLR reduces oral and oropharyngeal cancer risk .

What do these findings mean?

- These findings suggest that the results of previous observational studies examining the effect of statins on oral and oropharyngeal risk may have been confounded.
- Given we found little evidence of an effect of other cholesterol lowering therapies, the mechanism of action of PCSK9 may be independent of cholesterol-lowering. Further replication of this finding in other head and neck cancer datasets is required.

143 **Introduction**

144

145 Head and neck squamous cell carcinoma (HNSCC), which includes cancers of the oral
146 cavity (OC) and oropharynx (OPC), is the sixth most common cancer in the world, with over
147 550,000 new cases and 300,000 deaths annually [1, 2]. Despite some modest improvements
148 in the treatment of HNSCC, survival ranges between 19 - 59% at 10 years [3] and recurrence
149 rates remain high [4]. Patients often undergo a combination of surgery, radiotherapy and
150 chemotherapy which can result in significant morbidity [5]. Established risk factors include
151 smoking, alcohol and human papilloma virus (HPV), the latter mainly linked with
152 oropharyngeal cancer [6, 7]. Given that in contemporary cohorts, around 70% of OPC cases
153 (versus <5% of OC cases) are HPV driven and often present in younger populations, oral and
154 oropharyngeal tumours are considered distinct disease entities, with different risk factor
155 profiles [8]. Despite smoking cessation, alcohol reduction measures and the implementation
156 of HPV vaccination in some areas, HNSCC remains a major global health problem [2]. Novel
157 strategies for prevention of HNSCC are required, in particular for those at high risk and one
158 approach is to identify novel risk factors which can be easily modified, for example by
159 repurposing existing drugs [9].

160

161 Statins are one of the most commonly prescribed medications worldwide. They are
162 prescribed to reduce levels of circulating total and low-density lipoprotein cholesterol (LDL-
163 C), with proven preventative and therapeutic effects in cardiovascular disease and a good
164 safety profile [10, 11]. Statins inhibit 3-hydroxy-3-methylglutaryl-coenzyme A reductase
165 (HMG-CoA reductase (HMGCR)), the rate-limiting enzyme in the mevalonate pathway,
166 responsible for cholesterol and steroid hormone synthesis [12]. Other clinically approved

167 drugs that target cholesterol metabolism via different mechanisms include ezetimibe
168 (targeting Niemann-Pick C1-like protein (NPC1L1)) and proprotein convertase subtilisin/kexin
169 type 9 (PCSK9) inhibitors such as evolocumab or alirocumab. These agents act by reducing the
170 intestinal absorption of cholesterol or by enhancing uptake of LDL-C through increased
171 cellular membrane expression of the LDL-receptor (LDLR), respectively. Conversely,
172 cholesteryl ester transfer protein inhibitors (CETP) substantially increase levels of high-density
173 lipoprotein cholesterol (HDL-C), lower levels of LDL-C and enhance reverse cholesterol
174 transport [13].
175
176 Cholesterol is vital for a variety of key cellular functions, including membrane integrity,
177 signalling, protein synthesis and cell cycle progression. Therefore, modulation of cholesterol
178 synthesis has the potential to influence several hallmarks of tumourigenesis including cell
179 migration and proliferation [14]. In an experimental study, mice given oral daily doses of
180 simvastatin two weeks prior to subcutaneous injection of FaDu (HPV-negative
181 hypopharyngeal tumour cells), showed a significant reduction in tumour growth. This study
182 was designed to mimic a clinical scenario where patients who present with a tumour may
183 have been taking the medication prior to tumour initiation [15], and suggested that
184 simvastatin antagonises tumour metabolic reprogramming, another important hallmark of
185 cancer [15]. Mechanistic support for the role of LDL-C lowering in cancer development comes
186 largely from the fact that lipids are themselves major cell membrane components essential
187 for cell division and maintaining tissue integrity. Changes in lipid levels have been reported
188 associated with tumour development [16, 17].
189

190 However, the evidence that cholesterol-lowering drugs may reduce the risk of head
191 and neck cancer is limited. Some observational studies report an inverse association of taking
192 statins with both head and neck cancer risk and survival [14, 18], but others indicate little
193 evidence of any effect [19]. Observational studies are not randomised and are susceptible to
194 reverse causality and/or confounding [19]. Mendelian randomization (MR) is an approach
195 that uses germline genetic proxies (referred to as instruments) to help appraise causal effects
196 of potentially modifiable extrinsic exposures or intrinsic traits with disease [20-22]. It has also
197 been used to estimate therapeutic potential by investigating genetic variation at drug targets
198 [23]. Numerous single nucleotide polymorphisms (SNPs) are associated with lower levels of
199 circulating LDL-C [24, 25] and inheriting an LDL-C lowering allele has been proposed to be
200 analogous to being assigned life-long treatment with a cholesterol lowering drug [26]. In this
201 way, germline genetic variants may serve as proxies for exposure to potential
202 pharmacological agents which are less likely than observational measures to be subject to
203 reverse causation or confounding. Genetic proxies can therefore be used to predict both the
204 likely beneficial and adverse effects of long-term modulation of the drug targets on disease.
205
206 MR has previously demonstrated the protective effect of cholesterol-lowering drugs
207 on cardiovascular disease risk [27] , but also that inhibition of HMGCR and PCSK9 may have
208 an adverse effect on diabetes risk [28]. Of relevance to cancer, some recent MR studies have
209 shown that genetically-proxied inhibition of HMGCR may be protective against overall cancer
210 [29] and epithelial ovarian cancer [30] risk. Our aim was to use MR to appraise the causal
211 nature and mechanistic basis of the relationship between cholesterol-lowering and risk of oral
212 and oropharyngeal cancer by investigating germline variation in HMGCR, NPC1L1, CETP,
213 PCSK9 and LDLR, and other related lipid traits such as circulating LDL-C.

214

215 **Methods**

216

217 **Identifying cholesterol-lowering genetic instruments.** For the primary analysis, SNPs in
218 *HMGCR*, *NPC1L1*, *CETP, PCSK9* and *LDLR* were used to proxy the effect of lipid-lowering
219 therapies and to estimate the downstream effect of manipulating these targets on OC and
220 OPC risk. SNPs were identified within 100 kb on either side of the target gene (*HMGCR*,
221 *NPC1L1*, *CETP, PCSK9* and *LDLR)* that were associated with LDL-C levels. Variants were robustly
222 associated with LDL-C in a meta-analysis of genome-wide association studies (GWAS)
223 involving 188,578 individuals primarily (96%) of European ancestry in the Global Lipids
224 Genetic Consortium (GLGC) [25]. Linkage disequilibrium (LD) (r^2) was evaluated to check the
225 overlap between variants using LDmatrix (4.0 Release) [31]. Proxy SNPs were permitted to be
226 in weak LD (r^2 <0.2) with each other, to increase the proportion of variance explained in each
227 respective drug target therefore maximising instrument strength. Multiple papers have used
228 these genetic instruments at this threshold, to demonstrate causal effects in cardiovascular
229 disease [13, 27, 32], diabetes [28] and ovarian cancer [30]. In secondary analyses, SNPs were
230 used to proxy circulating levels of LDL-C, HDL-C, total triglyceride, total cholesterol,
231 apolipoprotein A and B. Betas represented the change in lipid trait levels per copy of the effect
232 allele. These SNPs were already independently (r^2 <0.001) associated with the respective traits
233 in large GWAS which have been described previously [25, 33].

234

235 **Summary level genetic data on oral and oropharyngeal cancer from GAME-ON.**
236 We estimated the effects of the cholesterol-lowering genetic variants on risk of OC and OPC
237 using GWAS performed on 6,034 cases and 6,585 controls from 12 studies which were part of

238 the Genetic Associations and Mechanisms in Oncology (GAME-ON) Network [34]. The study
239 population included participants from Europe (45.3%), North America (43.9%) and South
240 America (10.8%). Cancer cases comprised the following the International Classification of
241 Diseases (ICD) codes: oral cavity (C02.0-C02.9, C03.0-C03.9, C04.0-C04.9, C05.0-C06.9)
242 oropharynx (C01.9, C02.4, C09.0-C10.9), hypopharynx (C13.0-C13.9), overlapping (C14 and
243 combination of other sites) and 25 cases with unknown ICD code (other). A total of 954
244 individuals with cancers of hypopharynx, unknown code or overlapping cancers were
245 excluded. Genomic DNA isolated from blood or buccal cells was genotyped at the Center for
246 Inherited Disease Research (CIDR) using an Illumina OncoArray custom designed for cancer
247 studies by the OncoArray Consortium [35]. In GAME-ON, all SNPs with a call rate of <95% were
248 excluded. Given the ethnic heterogeneity of the study population, the dataset was divided by
249 geographical region and SNPs within each region that showed deviation from Hardy-
250 Weinberg Equilibrium (HWE) in controls ($p= <1 \times 10^{-7}$) were excluded. Principal component
251 analysis (PCA) was performed using approximately 10,000 common markers in low LD
252 ($r^2 <0.004$), minor allele frequency (MAF) >0.05 and 139 population outliers were removed.
253 Full details of the included studies, as well as the genotyping and imputation performed, have
254 been described previously [34, 36].
255
256 **Two-sample Mendelian randomization.** Two-sample MR was conducted using the
257 "TwoSampleMR" package in R (version 3.5.3), by integrating SNP associations for cholesterol-
258 lowering (sample 1) with those for OC and OPC in GAME-ON (sample 2). For those SNPs
259 instrumenting LDL-C lowering, we first extracted summary statistics for the associations with
260 OC and OPC from GAME-ON. We next performed harmonisation of the direction of effects
261 between the cholesterol-lowering exposures and outcome (OC or OPC) where, for each

262 variant, the allele designated the 'exposure allele' was associated with lower LDL-C levels and
263 palindromic SNPs were aligned when MAFs were <0.3 or were otherwise excluded. In our
264 primary analysis, four palindromic SNPs, one in *HMGCR* (rs2006760), the other in *PCSK9*
265 (rs2149041) and two in *CETP* (rs5880, rs9929488) were removed. In the secondary analysis
266 with other lipid traits, 11 palindromic SNPs (rs1936800, rs2288912, rs7112577, rs964184,
267 rs150617279, rs1883711, rs4722043, rs2156552, rs2954029, rs581080, rs7534572) were
268 removed.
269
270 Individual effect-estimates for each SNP were calculated using the Wald ratio, by
271 dividing the SNP-outcome association by the SNP-exposure association. Multiple SNPs were
272 then combined into multi-allelic instruments using the random-effects inverse-variance
273 weighted (IVW) meta-analysis method, for each of the genes *HMGCR*, *NPC1L1, CETP, PCSK9*
274 and *LDLR.* This meta-analysis was undertaken to increase the proportion of variance in drug
275 targets and LDL-C lowering explained by each instrument, and thus improve statistical power
276 and the precision of our estimates [37]. The analysis produced an estimate of the effect of
277 the risk factor on OC and OPC risk. As the instruments for *HMGCR*, *NPC1L1, CETP, PCSK9* and
278 *LDLR* were in weak LD (r^2 <0.2), we accounted for this correlation between SNPs in the primary
279 analysis using LDlink (4.0 Release) which employs Phase 3 (Version 5) of the 1000 Genomes
280 Project and variant rs numbers based on dbSNP. Correlation matrices were inserted as an
281 MRInput object [31], resulting in MR methods which altered the weightings for correlated
282 SNPs [38-40]. For circulating lipid traits, a more stringent r^2 <0.001 was already applied in the
283 initial GWAS [25], so we did not account further for correlation in the secondary analysis. We
284 computed odds ratios (OR) which represent the change in odds of oral and oropharyngeal
285 squamous cell carcinoma per genetically-proxied inhibition of the drug target, equivalent to

286 a 1 mg/dl decrease in LDL-C. The OR was scaled to be per 1 mmol/L decrease by dividing the
287 LDL-C lowering effect (beta) and standard error (se) measured in mg/dL by 38.7 [30]. The
288 betas and standard errors for *HMGCR*, *NPC1L1*, *CETP*, *PCSK9* and *LDLR* SNPs were also
289 converted to reflect the cholesterol-lowering effect, given the "TwoSampleMR" package
290 preference to automatically change these into a positive direction of effect (i.e. lipid
291 increasing). The correct direction of effect was checked using a positive control of coronary
292 heart disease from the CARDIoGRAM GWAS data [41]. MR was also used to examine the effect
293 of circulating levels of LDL-C, HDL-C, total triglyceride, total cholesterol, apolipoprotein A and
294 B levels directly with OC and OPC cancer risk. The ORs in this analysis represent the change in
295 odds of oral or oropharyngeal squamous cell carcinoma, per SD unit increase in lipid trait.
296
297 The IVW method can provide an unbiased effect estimate in the absence of horizontal
298 pleiotropy or when horizontal pleiotropy is balanced [42]. We therefore performed sensitivity
299 analyses to evaluate the potential for unbalanced horizontal pleiotropy, where genetic
300 variants influence two or more traits through independent biological pathways. To ensure the
301 genetic instrument was associated with the instrument it was proxying, estimates of the
302 proportion of variance in each risk factor explained by the instrument (R^2) and F-statistics
303 were generated. An F-statistic of <10 is indicative of a weak instrument which may be subject
304 to weak instrument bias. To account for directional pleiotropy, we compared the IVW results
305 with three MR sensitivity analyses, which each make different assumptions: MR Egger [43],
306 weighted median [44] and weighted mode [45]. While these three methods are best used
307 when genetic instruments consist of a large numbers of independent SNPs, since r^2 values
308 between SNPs in our instruments were low (r^2 <0.2), we a-priori decided to include them, with
309 a further sensitivity analysis to account for correlation in the MR Egger analysis. The weighted

310 median stipulates that at least 50% of the weight in the analysis stems from variants that are
311 valid instruments [44], while the weighted mode requires that the largest subset of
312 instruments which identify the same causal effect to be valid instruments [45]. MR-Egger can
313 provide unbiased estimates even when all SNPs in an instrument violate the exclusion
314 restriction assumption (i.e. affect the outcome by means other than via the risk factor of
315 interest). However, there must be negligible measurement error (NOME) [46] in the genetic
316 instrument and the InSIDE (Instrument Strength Independent of Direct Effect) assumption
317 must be satisfied [43]. Where there was evidence of violation of the NOME assumption, this
318 was assessed using the I^2 statistic and MR-Egger was performed with simulation extrapolation
319 (SIMEX) correction [46]. To further assess the robustness of findings, we examined evidence
320 of heterogeneity in the individual SNP estimates using the Cochran Q-statistic, which may
321 indicate the presence of invalid instruments (e.g. due to horizontal pleiotropy) [47]. Scatter
322 and leave-one-out plots were produced to evaluate influential outliers and MR-PRESSO
323 (Mendelian Randomization Pleiotropy RESidual Sum and Outlier) was used to detect and
324 correct for potential outliers (where Q-statistic $p < 0.05$) [48].
325
326 **Stratification by cancer subsite.** Given the difference in established aetiology (i.e. smoking,
327 alcohol and HPV) at each HNSCC subsite [6], we performed MR analyses with stratification by
328 cancer subsite to evaluate potential heterogeneity in effects. For this, we used GWAS
329 summary data on a subset of 2,641 OPC cases and 2,990 OC cases from the 6,034 HNSCC cases
330 and the 6,585 common controls in the GAME-ON GWAS [34].
331
332 **Replication in UK Biobank.** UK Biobank data was used as a replication dataset for primary
333 analyses. A GWAS was performed on 839 combined OC and OPC cases and 372,016 controls,

334 with two further stratified GWAS for OC (n= 357) and OPC (n= 494). UK Biobank is a large
335 population-based cohort study that recruited over 500,000 men and women aged between
336 37 and 73 years between 2006 and 2010 throughout the UK. It received ethical approval from
337 the National Health Service North West Centre for Research Ethics Committee (reference:
338 11/NW/0382). Details of genotyping quality control, phasing and imputation are described
339 elsewhere [49]. Participant records are linked to cancer registry data and HNSCC was grouped
340 using the same ICD-codes as described above. Squamous cell carcinoma cases were identified
341 using histology codes 8070 – 8078. UK Biobank GWAS analyses were adjusted for sex and
342 genotyping array and performed in BOLT-LMM, a mixed model that accounts for population
343 stratification and relatedness [50, 51]. Primary MR analyses as described above in GAME-ON
344 were repeated in UK Biobank data.
345
346 **Meta-analysis of results.** We performed both fixed-effects and random-effects meta-analysis
347 of the MR estimates in GAME-ON and UK Biobank using the R package 'meta'. However, we
348 focus more on the fixed-effects estimates since we assume that the causal effect is constant
349 between the studies [52]. Heterogeneity between study populations was assessed using I^2
350 statistic [53].
351
352 **Results**
353
354 **Primary analysis in GAME-ON.** In total, 5 SNPs in *HMGCR* (rs12916, rs17238484, rs5909,
355 rs2303152, rs10066707) were used to proxy HMG-CoA reductase inhibition (statins); 5 SNPs
356 in *NPC1L1* (rs217386, rs2073547, rs7791240, rs10234070, rs2300414) proxied NPC1L1
357 inhibition (ezetimibe); 6 SNPs in *CETP* (rs9989419, rs12708967, rs3764261, rs1800775,

358 rs1864163, rs289714) proxied CETP inhibition; 6 SNPs in *PCSK9* (rs11206510, rs2479409,
359 rs2479394, rs10888897, rs7552841, rs562556) proxied PCSK9 inhibition; 3 SNPs proxied
360 cholesterol-lowering in *LDLR* (rs6511720, rs1122608, rs688) (LDL-receptor inhibition). Further
361 details of these SNP effects are given in **Table 1**.
362
363 **Table 1.** Detailed summary of LDL-C lowering genetic variants in *HMGCR*, *NPC1L1*, *CETP*,
364 *PCSK9* and *LDLR* variants from the in Global Lipids Genetics Consortium (GLGC)

Target	SNP	Pathway	EA	OA	EAF	Beta	se	*P*-value
HMGCR	rs12916	LDL-C	T	C	0.57	-0.06061	0.003	7.79E-78
	rs17238484	LDL-C	G	T	0.75	-0.05184	0.005	1.35E-21
	rs5909	LDL-C	G	A	0.90	-0.05102	0.007	4.93E-13
	rs2303152	LDL-C	G	A	0.88	-0.03498	0.005	1.04E-09
	rs10066707	LDL-C	G	A	0.58	-0.0411	0.005	2.97E-19
	rs2006760*	LDL-C	C	G	0.81	-0.04407	0.006	1.67E-13
NPC1L1	rs217386	LDL-C	A	G	0.41	-0.02908	0.003	1.20E-19
	rs2073547	LDL-C	A	G	0.81	-0.03885	0.004	1.92E-21
	rs7791240	LDL-C	T	C	0.91	-0.03404	0.005	1.84E-10
	rs10234070	LDL-C	C	T	0.90	-0.02363	0.005	1.52E-06
	rs2300414	LDL-C	G	A	0.93	-0.02828	0.006	5.45E-06
CETP	rs3764261	LDL-C	A	C	0.29	-0.04471	0.004	2.22E-34
	rs1800775	LDL-C	A	C	0.48	-0.03487	0.003	8.54E-24
	rs1864163	LDL-C	G	A	0.73	-0.03698	0.004	7.97E-21
	rs9929488*	LDL-C	G	C	0.70	-0.03159	0.004	8.15E-13
	rs9989419	LDL-C	G	A	0.60	-0.02344	0.004	2.49E-12
	rs12708967	LDL-C	T	C	0.80	-0.02963	0.004	3.47E-11
	rs289714	LDL-C	A	G	0.79	-0.03032	0.005	2.85E-10
	rs5880*	LDL-C	G	C	0.94	-0.03979	0.008	1.59E-06
PCSK9	rs11206510	LDL-C	C	T	0.15	-0.06871	0.001	2.38E-53
	rs2479409	LDL-C	A	G	0.67	-0.05309	0.001	2.52E-50
	rs2149041*	LDL-C	C	G	0.84	-0.05259	0.001	1.44E-35
	rs2479394	LDL-C	A	G	0.72	-0.03192	0.001	1.58E-19
	rs10888897	LDL-C	T	C	0.40	-0.04192	0.001	8.43E-31
	rs7552841	LDL-C	C	T	0.63	-0.04589	0.001	5.40E-15
	rs562556	LDL-C	G	A	0.19	-0.05292	0.002	6.16E-21
LDLR	rs6511720	LDL-C	T	G	0.11	-0.17482	0.004	3.69E-54
	rs1122608	LDL-C	T	G	0.23	-0.05473	0.003	2.02E-86
	rs688	LDL-C	C	T	0.56	-0.04465	0.003	3.04E-48

365

366 EA, effect allele or low-density lipoprotein-cholesterol (LDL-C) lowering allele; OA = other or non-
367 effect allele; EAF, effect allele frequency; se= standard error. * Palindromic SNPs removed
368 Beta represents the change in LDL-C levels per copy of the effect allele. For SI conversion of mmol/L
369 to mg/dL, multiply by 38.7.
370
371 There was limited evidence of an effect of genetically-proxied inhibition of HMGCR
372 and NPC1L1 on combined OC and OPC risk (OR IVW 1.1; 95%CI 0.6, 1.9, p= 0.82 and 1.0; 95%
373 CI 0.4, 2.7, p= 0.99), respectively. (**Table 2** and **S1 Fig**). A similar result was found for
374 genetically-proxied LDL-C lowering inhibition of CETP on OC and OPC combined (OR IVW 1.3;
375 95%CI 0.6, 2.6, p= 0.49) (**Table 2 and S1 Fig**). However, higher risk of combined OC and OPC
376 was found in relation to genetically-proxied PCSK9 inhibition, equivalent to a 1 mmol/L (38.7
377 mg/dL) reduction in LDL-C (OR IVW 2.1; 95%CI 1.2, 3.4, p= 0.01; **Table 2 and Fig 1**). This is in
378 contrast to the reduction in odds seen in relation to cardiovascular disease using the same
379 instrument (OR IVW 0.6; 95%CI 0.4, 0.8, $p < 1 \times 10^{-03}$; **Fig 2**) in 60,801 cases and 123,504 control
380 subjects enrolled in the CARDIoGRAM consortia studies [41]. There was also some evidence
381 that LDLR variants, resulting in genetically-proxied reduction in LDL-C equivalent to a 1
382 mmol/L (38.7 mg/dL), reduced the risk of combined OC and OPC (OR IVW; 0.7; 95%CI 0.4, 1.0,
383 p= 0.05; **Table 2, Fig 1**).
384
385 **Fig 1. Forest plot showing the causal effects of *HMGCR*, *NPC1L1, CETP, PCSK9* and *LDLR***
386 **variants on the oral and oropharyngeal cancer subsites in GAME-ON**. Effect estimates on
387 oral and oropharyngeal cancer are reported on the log odds scale.
388

389 **Fig 2. Forest plots showing the causal effects of cholesterol-lowering PCSK9 and LDLR single**
390 **nucleotide polymorphisms on coronary heart disease and combined oral/ oropharyngeal**
391 **cancer in GAME-ON.** Effect estimates on oral and oropharyngeal cancer are reported on the
392 log odds scale.

393 **Table 2.** Mendelian randomization results of genetically-proxied inhibition of HMGCR, NPC1L1, CETP, PCSK9 and LDLR with risk of oral and

394 oropharyngeal cancer including sensitivity analyses in GAME-ON

395

					IVW		Weighted median		Weighted mode		MR-Egger	
	Outcome	**Exposure/ Outcome dataset**	**Outcome N**	**Number of SNPs**	**OR (95%CI)**	**P**	**OR (95%CI)**	**P**	**OR (95%CI)**	**P**	**OR (95%CI)**	**P**
HMGCR	Oral/ Oropharyngeal cancer	GAME-ON/ GLGC	6,034	5	1.07 (0.62, 1.84)	0.82	1.20 (0.63, 2.28)	0.58	1.20 (0.57, 2.50)	0.66	1.33 (0.07, 26.58)	0.86
	Oral cancer	GAME-ON/ GLGC	2,990	5	1.49 (0.75, 2.96)	0.25	1.66 (0.73, 3.78)	0.23	1.69 (0.65, 4.42)	0.35	1.25 (0.03, 55.80)	0.91
	Oropharyngeal cancer	GAME-ON/ GLGC	2,641	5	0.90 (0.43, 1.85)	0.77	1.01 (0.43, 2.34)	0.99	1.08 (0.44, 2.64)	0.88	0.77 (0.01, 45.07)	0.91
NPC1L1	Oral/ Oropharyngeal cancer	GAME-ON/ GLGC	6,034	5	1.01 (0.38, 2.69)	0.99	0.90 (0.29, 2.82)	0.86	0.86 (0.24, 3.08)	0.83	0.22 (0.00, 102.42)	0.66
	Oral cancer	GAME-ON/ GLGC	2,990	5	1.02 (0.30, 3.41)	0.98	1.20 (0.29, 5.05)	0.80	1.29 (0.22, 7.41)	0.79	0.09 (0.00, 160.66)	0.57
	Oropharyngeal cancer	GAME-ON/ GLGC	2,641	5	0.60 (0.16, 2.25)	0.45	0.60 (0.12, 3.04)	0.53	0.60 (0.10, 3.73)	0.62	0.20 (0.01, 688.64)	0.72
CETP	Oral/ Oropharyngeal cancer	GAME-ON/ GLGC	6,034	6	1.28 (0.64, 2.55)	0.49	1.24 (0.54, 2.81)	0.61	1.25 (0.43, 3.64)	0.71	0.82 (0.02, 27.60)	0.92
	Oral cancer	GAME-ON/ GLGC	2,990	6	1.65 (0.70, 3.88)	0.25	1.69 (0.61, 4.70)	0.31	1.63 (0.43, 5.87)	0.49	0.42 (0.01, 32.58)	0.72
	Oropharyngeal cancer	GAME-ON/ GLGC	2,641	6	1.12 (0.45, 2.77)	0.81	1.05 (0.35, 3.20)	0.93	0.73 (0.17, 3.07)	0.69	1.50 (0.02, 142.22)	0.87

PCSK9	Oral/ Oropharyngeal cancer	GAME-ON/ GLGC	6,034	6	2.05 (1.24, 3.38)	0.01	2.21 (1.12, 4.08)	0.01	2.19 (0.81, 5.92)	0.18	1.83 (0.17, 20.00)	0.65
	Oral cancer	GAME-ON/ GLGC	2,990	6	1.62 (0.89, 2.94)	0.11	1.80 (0.90, 3.62)	0.10	2.00 (0.73, 5.48)	0.23	2.17 (0.15, 32.13)	0.60
	Oropharyngeal cancer	GAME-ON/ GLGC	2,641	6	3.49 (1.58, 7.68)	2.00 E-03	3.19 (1.40, 7.26)	0.01	2.73 (0.86, 8.70)	0.15	1.99 (0.04, 92.11)	0.74
LDLR	Oral/ Oropharyngeal cancer	GAME-ON/ GLGC	6,034	3	0.65 (0.42, 1.00)	0.05	0.71 (0.47, 1.08)	0.11	0.74 (0.47, 1.15)	0.31	0.90 (0.41, 1.95)	0.83
	Oral cancer	GAME-ON/ GLGC	2,990	3	0.53 (0.32, 0.87)	0.01	0.56 (0.32, 0.98)	0.04	0.57 (0.32, 1.04)	0.21	0.56 (0.18, 1.76)	0.50
	Oropharyngeal cancer	GAME-ON/ GLGC	2,641	3	0.90 (0.53, 1.52)	0.69	0.91 (0.55, 1.53)	0.73	1.08 (0.62, 1.89)	0.81	1.56 (0.64, 3.82)	0.51

Abbreviations: IVW, inverse variance weighted; OR, odds ratio; CI, confidence intervals; P, *p*-value.

OR represents the exponential change in odds of oral/ oropharyngeal squamous cell carcinoma per genetically-proxied inhibition of drug target equivalent to a 1 mmol/L decrease in LDL-C.

401 **Stratification by cancer subsite in GAME-ON.** When stratified by subsite, the adverse
402 effect of PCSK9 appeared to be mainly in the oropharynx, (OR IVW 3.5; 95%CI 1.6, 7.7, p= 2
403 $x10^{-03}$), with limited evidence in the oral cavity (OR IVW 1.6; 0.9, 2.94, p= 0.11) (**Table 2 & Fig**
404 **1**). The effects appeared stronger in OPC versus OC, but with overlapping confidence intervals.
405 LDLR was associated with a reduction in risk of OC (OR IVW 0.5; 95%CI 0.3, 0.9, p= 0.01), but
406 there was little evidence of an association with OPC (OR IVW 0.9; 95%CI 0.5, 1.5, p= 0.69)
407 (**Table 2 and Fig 1**). For both PCSK9 and LDLR associations, the direction of effect was generally
408 consistent across the four MR methods tested (**Table 2**).
409
410 **Secondary analysis in GAME-ON.** SNPs were also used to proxy circulating levels of LDL-C (77
411 SNPs), high-density lipoprotein cholesterol (HDL-C) (85 SNPs), total triglyceride (54 SNPs),
412 total cholesterol (82 SNPs), apolipoprotein A (9 SNPs) and apolipoprotein B (14 SNPs) (**S1**
413 **Table**). There was limited evidence of an effect of any of these other lipid traits on either OC
414 or OPC (**Table 3 and S2 Fig**).
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433

434 **Table 3.** Mendelian randomization results of circulating lipid traits with risk of oral and

435 oropharyngeal cancer in GAME-ON

Target	N SNPs	Outcome	IVW OR (95% CI)	*P*-value
LDL-C	77	Oral/ Oropharyngeal cancer	0.98 (0.87, 1.11)	0.79
		Oral cancer	0.99 (0.85, 1.15)	0.88
		Oropharyngeal cancer	1.03 (0.87, 1.21)	0.76
HDL-C	85	Oral/ Oropharyngeal cancer	0.98 (0.83, 1.16)	0.79
		Oral cancer	1.08 (0.88, 1.32)	0.45
		Oropharyngeal cancer	0.87 (0.71, 1.05)	0.15
Total triglycerides	54	Oral/ Oropharyngeal cancer	1.19 (1.01, 1.04)	0.04
		Oral cancer	1.19 (0.96, 1.46)	0.11
		Oropharyngeal cancer	1.19 (0.96, 1.47)	0.12
Total cholesterol	82	Oral/ Oropharyngeal cancer	1.04 (0.91, 1.18)	0.55
		Oral cancer	1.09 (0.93, 1.28)	0.30
		Oropharyngeal cancer	1.00 (0.84, 1.20)	0.96
Apolipoprotein A	9	Oral/ Oropharyngeal cancer	0.87 (0.73, 1.03)	0.11
		Oral cancer	0.90 (0.73, 1.12)	0.34
		Oropharyngeal cancer	0.82 (0.65, 1.04)	0.10
Apolipoprotein B	14	Oral/ Oropharyngeal cancer	1.04 (0.88, 1.22)	0.67
		Oral cancer	1.15 (0.89, 1.49)	0.29
		Oropharyngeal cancer	1.00 (0.83, 1.21)	0.98

436

437 Abbreviations: IVW, inverse variance weighted; OR, odds ratio; CI, confidence intervals.

438 IVW OR represents the exponential change in odds of oral/ oropharyngeal squamous cell carcinoma
439 per SD increase in the circulating lipid trait (one SD for LDL-C = 38.7 mg/dL, HDL-C = 15.5 mg/dL,
440 Apolipoprotein A = 0.32 g/L, Apolipoprotein B = 0.52 g/L, Total triglycerides = 90.7 mg/dL, Total
441 cholesterol = 41.8 mg/dL).

442 **Sensitivity analyses.** IVW, MR Egger, weighted median, simple and weighted mode were
443 carried out, in addition to IVW analysis accounting for LD structure (**S2.1-2.5 Tables**). The
444 results adjusting for SNP correlation followed the same pattern as the main results (**S3 Table**).
445 There was limited evidence of weak instrument bias being present (F-statistic >10) and the
446 proportion of variance in the phenotype (R^2) explained by the genetic instruments ranged
447 from 0.1 to 6% (**S4 Table**). In both primary and secondary analyses there was limited evidence
448 of heterogeneity in the SNP effect estimates for IVW and MR Egger regression, except for in
449 HDL-C (Q IVW 115.7, p= 0.01; Q MR Egger 115.6, p= 0.01) (**S5 and S6 Tables**).
450
451 MR Egger intercepts also indicated limited evidence of directional pleiotropy (**S7 and**
452 **S8 Tables**). For the primary analysis there were no clear outliers in both scatter and leave-
453 one-out plots (**Fig 3 and S3-6 Figs**) and MR-PRESSO detected no individual outliers (**S9 Table**).
454 Where there was evidence of violation of the NOME assumption for the HMGCR, NPC1L1 and
455 CETP instruments (i.e. I^2 statistic <0.90) (**S10 Table**), MR-Egger was performed with SIMEX
456 correction and effects were still consistent with the null (**S11 Table**).
457
458 **Fig 3. Scatter plots for LDLR and PCSK9 single nucleotide polymorphisms effect on combined**
459 **oral/ oropharyngeal cancer in GAME-ON.**
460
461 **Replication in UK Biobank and meta-analysis of results.** Primary MR analyses as described
462 above were replicated in UK Biobank, showing limited evidence of an effect of genetically-
463 proxied inhibition of HMGCR, NPC1L1, CETP, PCSK9 and LDLR on risk of OC and OPC (**S12**
464 **Table**). Following IVW fixed-effects meta-analysis of GAME-ON and UK Biobank MR results,
465 there was a consistently strong effect of genetically-proxied PSCK9 inhibition on combined

466 OC and OPC (OR IVW 1.8; 95%CI 1.2, 2.8), with good concordance between studies (I^2= 22%)
467 and methods used (**Fig 4** and **S7 Fig**). Effects for PCSK9 appeared stronger in relation to OPC
468 (OR IVW 2.6; 95%CI 1.4, 4.9) than OC (OR IVW 1.4; 95%CI 0.8, 2.4), but with moderate
469 heterogeneity between studies (I^2= 41%) (**Fig 4**). Conversely, the protective effect for LDLR on
470 OC and OPC combined was also consistent in the meta-analysis (OR IVW 0.7; 95%CI 0.5, 1.0),
471 with good concordance between studies (I^2= 0%) (**Fig 5** and **S7 Fig**). However, the protective
472 effect seen specifically in relation to OC in GAME-ON (OR IVW 0.5; 95%CI 0.3, 0.9) was not
473 replicated in UK Biobank (OR IVW 1.6; 95%CI 0.5, 4.8), with strong evidence of heterogeneity
474 between the studies (I^2= 66%).
475
476 **Fig 4. Forest plots showing inverse variance weighted meta-analysis effects of cholesterol-**
477 **lowering *PCSK9* single nucleotide polymorphisms on head and neck cancer subsites.**
478
479 **Fig 5. Forest plots showing inverse variance weighted meta-analysis effects of cholesterol-**
480 **lowering *LDLR* single nucleotide polymorphisms on head and neck cancer subsites.**
481
482 **Discussion**
483
484 We found limited evidence for a role of cholesterol-lowering in OC and OPC risk. This
485 included the absence of a protective effect of genetically-proxied inhibition of HMGCR,
486 suggesting previous observational studies investigating the relationship between statins and
487 head and neck cancer risk may be subject to residual confounding or bias. However, we did
488 observe an adverse effect of PCSK9 inhibition on OC and OPC risk, which was of a similar
489 magnitude to the protective effect seen in relation to cardiovascular disease using the same

490 genetic instrument (**Fig 2**). This PCSK9 effect was evident in both the GAME-ON (n= 6,034 OC
491 and OPC cases and n= 6,585 controls) and UK Biobank datasets (n= 839 OC and OPC cases and
492 n= 372,016 controls). We also found some evidence for a protective effect of cholesterol-
493 lowering variants in *LDLR* on OC and OPC risk in both studies. The IVW analysis for HMGCR,
494 NPC1L1, CETP, PCSK9 and LDLR accounting for LD structure (r^2 <0.2) followed the same
495 pattern as the main results (**S3 Table**).
496
497 **Association between PCSK9, LDLR and cancer risk.** Despite the lack of consistent evidence
498 for a role of cholesterol-lowering on risk of OC or OPC in this study, individual effects of both
499 PCSK9 and LDLR were demonstrated which may implicate a role for these drug targets in the
500 development of OC or OPC via other mechanisms. The effects identified in the present study
501 are directionally consistent with a recent MR analysis of 1,615 combined head and neck
502 cancer cases from UK Biobank, which also found that a 1 SD unit increase in LDL-C proxied by
503 PCSK9 and LDLR was associated with a reduction (OR 0.7 95%CI 0.4, 1.4, p= 0.35) and increase
504 in odds (OR 1.6 95%CI 1.0, 2.4, p= 0.05) of head and neck cancer, respectively [29]. The
505 opposing effects of PCSK9 and LDLR in this study also suggests that cholesterol lowering is
506 unlikely to be the main mechanism of action. However, this previous analysis is limited by the
507 relatively small number of cases and heterogeneity of head and neck cancer subtypes, with
508 no selection for the histological subtype of squamous cell carcinoma. In the present study, we
509 focused specifically on oral and oropharyngeal subtypes of HNSCC.
510
511 Beyond the established role of *PCSK9* in cholesterol homeostasis, other potential
512 pleiotropic effects are not well understood. Variants in *PCSK9* have been associated with an
513 increased risk of diabetes (OR 1.1, 95%CI 1.0, 1.2 for each 10 mg per decilitre decrease in LDL-

514 C) [28]. However, a recent phenome-wide association study (PheWAS) did not find *PCSK9*
515 or *LDLR* to be correlated with any non-lipid-related phenotypes, including diabetes [54].
516 There is limited *in vivo* and *in vitro* evidence that *PCSK9* might be involved in both cell
517 proliferation and apoptosis. The gene was initially designated as NARC1 (neural apoptosis-
518 regulated convertase 1), involved in apoptosis of cerebellar neurons [55] and *PCSK9* has since
519 been found to be upregulated in some cancers [56, 57].
520
521 One suggested mechanism for a link with cancer progression is that the increased
522 expression of *PCSK9* prevents LDL-receptor (LDLR) recycling, leading to
523 hypercholesterolaemia and more exogenous lipid to support the proliferation of the tumour
524 [55]. Our study suggests the opposite, that genetically-proxied inhibition of *PCSK9* results in
525 an increased risk of OC or OPC. We hypothesise that access to intracellular LDL-C could in fact
526 be pro-tumourigenic, providing a favourable environment for a developing tumour cell,
527 maintaining membrane integrity and promoting cell division. Therapies such as statins,
528 ezetimibe, and PCSK9 inhibitors may all lower LDL-C level through the upregulation of LDL-
529 receptors, resulting in elevated intracellular cholesterol. However, cancer mechanisms are
530 often context dependent and perhaps only the expression of *PCSK9* and *LDLR* is relevant in
531 head and neck cancer. CETP inhibitors instead block the transfer of cholesteryl ester from
532 HDL-C to LDL-C, thereby raising HDL-C and lowering LDL-C (and apolipoprotein B), as well as
533 enhancing reverse cholesterol transport [58]. Unlike statins, CETP inhibitors do not appear to
534 increase the risk of type 2 diabetes, thought to be as a result of pancreatic islet cell cholesterol
535 accumulation with use of other cholesterol-lowering drugs [59]. Therefore, the absence of
536 effect when proxying *CETP* inhibition in this study, supports the possible mechanism of LDL-C
537 uptake via the LDL-receptor in OC or OPC.

538

539 While both *PCSK9* [60] and *LDLR* [61] are expressed in head and neck tumours, this was not
540 evident in normal oral or oropharyngeal tissue, and sufficient tissue is currently not available
541 in expression datasets [62]. Recent studies have associated elevated *PCSK9* with alcohol use
542 disorder, including the interesting possibility of using anti-PSCK9 monoclonal antibodies for
543 the treatment of alcoholic liver disease [63, 64]. Given that alcohol is a well-known risk factor
544 for HNSCC, this pleiotropy could have partially explained the effect seen in our study, however
545 we proxied the inhibition of *PCSK9* and so would have expected to see a protective effect of
546 this gene in HNSCC cases who may have been heavy alcohol drinkers. Further investigation is
547 required to untangle the relationship between *PCSK9*, alcohol and head and neck cancer.

548

549 **Comparison with previous studies.** It is believed that statins could play a potential role in
550 cancer chemoprevention which may reduce the risk of some site-specific cancers such as
551 prostate [65] and ovarian [30], but not all. Some of these studies have reported cancer risk
552 reductions by as much as 50 – 65% [66-68]. However, meta-analyses and clinical trials have
553 contradicted these findings [69, 70]. In addition to confounding, immortal time bias likely
554 inflated observational results because, to be classified as a long-term statin user necessitates
555 that users survived without cancer over a long period [19, 71]. Dickerman et al. used
556 electronic records from 733,804 adults with 10-year follow-up to emulate a trial design. To
557 achieve this a pre-specified protocol was set, including eligibility criteria and checks were
558 made to ensure effect estimates for statins on cancer were comparable between the large
559 observational dataset and trial. The authors found little indication that statin therapy
560 influences cancer incidence, which was consistent with the analyses of randomised trials (with
561 a 10-year cancer-free survival difference of −0.3% 95%CI −1.5%, 0.5%) [19]. Nonetheless,

562 recent MR studies [29, 30] have identified an association between variants in *HMGCR* with
563 cancer risk, but not alternative cholesterol-lowering treatments or genetically-predicted LDL-
564 C, suggesting that statins may reduce cancer risk through a cholesterol independent pathway.
565 A recent case-control study of over 11,000 participants found an inverse association between
566 statin use and the occurrence of HNSCC (OR 0.86, 95%CI 0.77, 0.95, p= <0.01, of prior statin
567 exposure for cases compared to propensity score-matched controls) [18]. However, a wider
568 systematic review found that the evidence for the role of statins in the prevention of HNSCC
569 was limited [72]. As HNSCC incidence is a rare outcome, randomised controls trials are not
570 feasible, so we must be cautious interpreting the available observational findings given the
571 potential for bias and confounding as discussed previously.
572
573 In contrast to previous MR studies assessing overall cancer risk [29] and ovarian
574 specific risk [30], the MR carried out here in relation to OC and OPC showed no effect using
575 genetic instruments for HMGCR (statins). There was also limited evidence for a causal effect
576 of NPC1L1 (ezetimibe), CETP (CETP inhibitors) as well as a number of other circulating lipid
577 traits on OC or OPC. Therefore, it remains unclear as to whether the effects observed with
578 PCSK9 and LDLR are via LDL-C lowering or another less well-established pathway [73, 74], such
579 as receptor regulation for viral entry, synthesis of sex hormones and resultant dysregulated
580 metabolism [75-77].
581
582 **Strengths and limitations of this study.** Protective associations between cholesterol-lowering
583 therapies such as statins and head and neck cancer risk seen in previous observational studies
584 could be a result of reverse causation, immortal time bias, lack of randomisation or
585 confounding by socioeconomic status, smoking or HPV infection, for example. Our study

586 applied MR in an attempt to overcome these issues, using the largest number of SNPs
587 identified from the latest GWAS for both cholesterol-lowering and head and neck cancer that
588 could be identified in the literature [25, 34]. A series of pleiotropy-robust MR methods and
589 outlier detection were applied to rigorously explore the possibility that findings were not
590 biased as a result of pleiotropy. However, there was no HPV data available in these summary
591 results to enable more detailed stratified analysis of OPC. We did replicate findings for PCSK9
592 and LDLR, but the number of cases are low. Finally, most participants in the GAME-ON
593 network [34] were of European or North American decent, with only around 11% from South
594 America, and participants included in the UK Biobank analysis were exclusively of European
595 descent, so more work is required to determine if our results translate to other ancestry
596 groups.
597
598 In conclusion, our MR analyses provided little evidence for a role of cholesterol
599 lowering in OC or OPC risk although effects of genetically-proxied inhibition of *PCSK9* and
600 cholesterol-lowering variants in *LDLR* were observed in relation to OPC and OC risk. Given the
601 lack of a common pathway to carcinogenesis in OC or OPC, metabolic targets that may be
602 common to all tumours, regardless of the activated molecular pathway, could help simplify a
603 preventative or therapeutic approach [78]. Replication of our findings in other head and neck
604 cancer datasets and use of individual-level follow-up data with HPV status could provide
605 further insight into the effect of these genetic instruments on risk, treatment outcomes and
606 survival in head and neck cancer. With more evidence, future randomised control trials could
607 focus on treating high risk OC or OPC groups, such as those with severe dysplasia or who are
608 HPV-16 E6 positive, with cholesterol-lowering therapies.
609

610 **Data availability statement**

611

612 Summary-level analysis was conducted using publicly available GWAS data [25, 33].
613 Full summary statistics for the GAME-ON GWAS can be accessed via dbGAP (OncoArray: Oral
614 and Pharynx Cancer; study accession number: phs001202.v1.p1) [34]. Access to UK Biobank
615 (https://www.ukbiobank.ac.uk/) data is available to researchers through application.

616

617 **Code availability statement**

618

619 Two-sample MR analyses were conducted using the "TwoSampleMR" package in R
620 (version 3.5.3). A copy of the code used in this analysis will be made available at:
621 https://github.com/rcrichmond/cholesterol_lowering_headandneckcancer

622

623 ## Acknowledgements

624

625 M.G. was a National Institute for Health Research (NIHR) academic clinical fellow and
626 is currently supported by a Wellcome Trust GW4-Clinical Academic Training PhD Fellowship.
627 This research was funded in part, by the Wellcome Trust [Grant number 220530/Z/20/Z]. For
628 the purpose of open access, the author has applied a CC BY public copyright licence to any
629 Author Accepted Manuscript version arising from this submission. UK Biobank approval was
630 given for this project (ID 40644 "Investigating aetiology, associations and causality in diseases
631 of the head and neck") and UK Biobank GWAS data was also accessed under the application
632 (ID 15825 "MR-Base: an online resource for Mendelian randomization using summary data"-

633 Dr Philip Haycock). R.C.R. is a de Pass VC research fellow at the University of Bristol. J.T. is
634 supported by an Academy of Medical Sciences (AMS) Springboard award, which is supported
635 by the AMS, the Wellcome Trust, Global Challenges Research Fund (GCRF), the Government
636 Department of Business, Energy and Industrial strategy, the British Heart Foundation and
637 Diabetes UK (SBF004\1079). R.M.M. was supported by a Cancer Research UK
638 (C18281/A19169) programme grant (the Integrative Cancer Epidemiology Programme) and is
639 part of the Medical Research Council Integrative Epidemiology Unit at the University of Bristol
640 supported by the Medical Research Council (MC_UU_12013/1, MC_UU_12013/2, and
641 MC_UU_12013/3) and the University of Bristol. JY is supported by a Cancer Research UK
642 Population Research Postdoctoral Fellowship (C68933/A28534). R.M.M. and A.R.N. are
643 supported by the National Institute for Health Research (NIHR) Bristol Biomedical Research
644 Centre which is funded by the National Institute for Health Research (NIHR) and is a
645 partnership between University Hospitals Bristol and Weston NHS Foundation Trust and the
646 University of Bristol. This publication presents data from the Head and Neck 5000 study. The
647 study was a component of independent research funded by the NIHR under its Programme
648 Grants for Applied Research scheme (RP-PG-0707-10034). The views expressed in this
649 publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the
650 Department of Health. Core funding was also provided through awards from Above and
651 Beyond, University Hospitals Bristol Research Capability Funding and the NIHR Senior
652 Investigator award to A.R.N. Human papillomavirus (HPV) serology was supported by a Cancer
653 Research UK Programme Grant, the Integrative Cancer Epidemiology Programme (grant
654 number: C18281/A19169). B.D. and the University of Pittsburgh head and neck cancer case-
655 control study are supported by US National Institutes of Health (NIH) grants: P50 CA097190,
656 P30 CA047904 and R01 DE025712. The genotyping of the HNSCC cases and controls was

657 performed at the Center for Inherited Disease Research (CIDR) and funded by the US National
658 Institute of Dental and Craniofacial Research (NIDCR; 1X01HG007780-0). The University of
659 North Caroline (UNC) CHANCE study was supported in part by the National Cancer Institute
660 (R01-CA90731). E.E.V and D.L are supported by Diabetes UK (17/0005587). E.E.V is also
661 supported by the World Cancer Research Fund (WCRF UK), as part of the World Cancer
662 Research Fund International grant programme (IIG_2019_2009). E.H.T and P.S. were
663 supported by the GENCAPO/FAPESP grant (10/51168-0).
664

665 **Competing Interests**

666 The authors declare no conflicts of interest. The funders had no role in the design of
667 the study; the collection, analysis, and interpretation of the data; the writing of the
668 manuscript; and the decision to submit the manuscript for publication. The authors alone are
669 responsible for the views expressed in this article.

670

671 **References**

672
673 1. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral
674 Oncol. 2009;45(4-5):309-16.

675 2. Saba NF, Goodman M, Ward K, Flowers C, Ramalingam S, Owonikoko T, et al. Gender
676 and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral
677 tongue, base of tongue, and tonsils: a surveillance, epidemiology and end results program-
678 based analysis. Oncology. 2011;81(1):12-20.

679 3. Cancer Research UK (CRUK). Head and neck cancer statistics 2019 [cited 2019
680 11/04/2019]. Available from: https://www.cancerresearchuk.org/health-
681 professional/cancer-statistics/statistics-by-cancer-type/head-and-neck-cancers#heading-
682 Two.

683 4. Mehanna H, Kong A, Ahmed SK. Recurrent head and neck cancer: United Kingdom
684 National Multidisciplinary Guidelines. J Laryngol Otol. 2016;130(S2):S181-S90.

685 5. De Boer MF, McCormick LK, Pruyn JF, Ryckman RM, van den Borne BW. Physical and
686 psychosocial correlates of head and neck cancer: a review of the literature. Otolaryngol
687 Head Neck Surg. 1999;120(3):427-36.

688 6. Thomas SJ, Penfold CM, Waylen A, Ness AR. The changing aetiology of head and neck
689 squamous cell cancer: A tale of three cancers? Clin Otolaryngol. 2018;43(4):999-1003.

690 7. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human
691 papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med.
692 2010;363(1):24-35.

693 8. Elrefaey S, Massaro MA, Chiocca S, Chiesa F, Ansarin M. HPV in oropharyngeal
694 cancer: the basics to know in clinical practice. Acta Otorhinolaryngol Ital. 2014;34(5):299-
695 309.

696 9. Sleire L, Forde HE, Netland IA, Leiss L, Skeie BS, Enger PO. Drug repurposing in
697 cancer. Pharmacol Res. 2017;124:74-91.

698 10. Hu M, Cheung BM, Tomlinson B. Safety of statins: an update. Ther Adv Drug Saf.
699 2012;3(3):133-44.

700 11. Audi S, Burrage DR, Lonsdale DO, Pontefract S, Coleman JJ, Hitchings AW, et al. The
701 'top 100' drugs and classes in England: an updated 'starter formulary' for trainee
702 prescribers. British Journal of Clinical Pharmacology. 2018;84(11):2562-71.

703 12. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA
704 reductase. Science. 2001;292(5519):1160-4.

705 13. Ference BA, Kastelein JJP, Ginsberg HN, Chapman MJ, Nicholls SJ, Ray KK, et al.
706 Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein
707 Levels and Cardiovascular Risk. JAMA. 2017;318(10):947-56.

708 14. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin Use and Reduced Cancer-Related
709 Mortality. New Engl J Med. 2012;367(19):1792-802.

710 15. Mehibel M, Ortiz-Martinez F, Voelxen N, Boyers A, Chadwick A, Telfer BA, et al.
711 Statin-induced metabolic reprogramming in head and neck cancer: a biomarker for targeting
712 monocarboxylate transporters. Sci Rep. 2018;8(1):16804.

713 16. Chawda JG, Jain SS, Patel HR, Chaduvula N, Patel K. The relationship between serum
714 lipid levels and the risk of oral cancer. Indian J Med Paediatr Oncol. 2011;32(1):34-7.

715 17. Mehta R, Gurudath S, Dayansoor S, Pai A, Ganapathy KS. Serum lipid profile in
716 patients with oral cancer and oral precancerous conditions. Dent Res J (Isfahan).
717 2014;11(3):345-50.

718 18. Kao LT, Hung SH, Kao PF, Liu JC, Lin HC. Inverse association between statin use and
719 head and neck cancer: Population-based case-control study in Han population. Head Neck-J
720 Sci Spec. 2019;41(5):1193-8.

721 19. Dickerman BA, Garcia-Albeniz X, Logan RW, Denaxas S, Hernan MA. Avoidable flaws
722 in observational analyses: an application to statins and cancer. Nat Med. 2019;25(10):1601-
723 6.

724 20. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology
725 contribute to understanding environmental determinants of disease? Int J Epidemiol.
726 2003;32(1):1-22.

727 21. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal
728 inference in epidemiological studies. Hum Mol Genet. 2014;23(R1):R89-98.

729 22. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a
730 guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601.

731 23. Walker VM, Smith GD, Davies NM, Martin RM. Mendelian randomization: a novel
732 approach for the prediction of adverse drug events and drug repurposing opportunities. Int J
733 Epidemiol. 2017;46(6):2078-89.

734 24. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al.
735 Biological, clinical and population relevance of 95 loci for blood lipids. Nature.
736 2010;466(7307):707-13.

737 25. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al.
738 Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45(11):1274-+.

739 26. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-
740 density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic,

741 epidemiologic, and clinical studies. A consensus statement from the European
742 Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-72.

743 27. Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally random
744 allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease
745 mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian
746 randomization study. J Am Coll Cardiol. 2015;65(15):1552-61.

747 28. Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, et al.
748 Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. N Engl J
749 Med. 2016;375(22):2144-53.

750 29. Carter P, Vithayathil M, Kar S, Potluri R, Mason AM, Larsson SC, et al. Predicting the
751 effect of statins on cancer risk using genetic variants: a Mendelian randomization study in
752 UK Biobank. medRxiv. 2020:2020.02.28.20028902.

753 30. Yarmolinsky J, Bull CJ, Vincent EE, Robinson J, Walther A, Smith GD, et al. Association
754 Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian
755 Cancer. JAMA. 2020;323(7):646-55.

756 31. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-
757 specific haplotype structure and linking correlated alleles of possible functional variants.
758 Bioinformatics. 2015;31(21):3555-7.

759 32. Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, et al. Mendelian
760 Randomization Study of ACLY and Cardiovascular Disease. N Engl J Med. 2019;380(11):1033-
761 42.

762 33. Kettunen J, Demirkan A, Wurtz P, Draisma HH, Haller T, Rawal R, et al. Genome-wide
763 study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA.
764 Nat Commun. 2016;7:11122.

765 34. Lesseur C, Diergaarde B, Olshan AF, Wunsch V, Ness AR, Liu G, et al. Genome-wide
766 association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer.
767 Nat Genet. 2016;48(12):1544-50.

768 35. Consortium O. Consortium launches genotyping effort. Cancer Discov.
769 2013;3(12):1321-2.

770 36. Dudding T, Johansson M, Thomas SJ, Brennan P, Martin RM, Timpson NJ. Assessing
771 the causal association between 25-hydroxyvitamin D and the risk of oral and oropharyngeal
772 cancer using Mendelian randomization. Int J Cancer. 2018;143(5):1029-36.

773 37. Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian
774 randomization studies. Int J Epidemiol. 2013;42(5):1497-501.

775 38. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing
776 Mendelian randomization analyses using summarized data. Int J Epidemiol.
777 2017;46(6):1734-9.

778 39. Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG. Using published data
779 in Mendelian randomization: a blueprint for efficient identification of causal risk factors. Eur
780 J Epidemiol. 2015;30(7):543-52.

781 40. Burgess S, Dudbridge F, Thompson SG. Combining information on multiple
782 instrumental variables in Mendelian randomization: comparison of allele score and
783 summarized data methods. Stat Med. 2016;35(11):1880-906.

784 41. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive
785 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease.
786 Nat Genet. 2015;47(10):1121-30.

787 42. Hemani G, Bowden J, Smith GD. Evaluating the potential role of pleiotropy in
788 Mendelian randomization studies. Hum Mol Genet. 2018;27(R2):R195-R208.

789 43. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid
790 instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol.
791 2015;44(2):512-25.

792 44. Bowden J, Smith GD, Haycock PC, Burgess S. Consistent Estimation in Mendelian
793 Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet
794 Epidemiol. 2016;40(4):304-14.

795 45. Hartwig FP, Smith GD, Bowden J. Robust inference in summary data Mendelian
796 randomization via the zero modal pleiotropy assumption. Int J Epidemiol. 2017;46(6):1985-
797 98.

798 46. Bowden J, Del Greco MF, Minelli C, Smith GD, Sheehan NA, Thompson JR. Assessing
799 the suitability of summary data for two-sample Mendelian randomization analyses using
800 MR-Egger regression: the role of the I-2 statistic. Int J Epidemiol. 2016;45(6):1961-74.

801 47. Bowden J, Spiller W, Del Greco F, Sheehan N, Thompson J, Minelli C, et al. Improving
802 the visualization, interpretation and analysis of two-sample summary data Mendelian
803 randomization via the Radial plot and Radial regression. Int J Epidemiol. 2018;47(4):1264-78.

804 48. Verbanck M, Chen CY, Neale B, Do R. Publisher Correction: Detection of widespread
805 horizontal pleiotropy in causal relationships inferred from Mendelian randomization
806 between complex traits and diseases. Nat Genet. 2018;50(8):1196.

807 49. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. Genome-wide
808 genetic data on ~500,000 UK Biobank participants. bioRxiv. 2017:166298.

809 50. Mitchell R, Hemani, G, Dudding, T, Corbin, L, Harrison, S, Paternoster, L. UK Biobank
810 Genetic Data: MRC-IEU Quality Control, version 2.
811 https://doi.org/10.5523/bris.1ovaau5sxunp2cv8rcy88688v. 2019.

812 51. Mitchell R, Elsworth BL, Raistrick CA, Paternoster L, Hemani G, Gaunt TR MRC IEU UK
813 Biobank GWAS pipeline version 2. https://doi.org/10.5523/bris.pnoat8cxo0u52p6ynfaekeigi.
814 2019.

815 52. Schwarzer G. meta: an R package for metaanalysis. R News. 2007;7:40-5.

816 53. Higgins SG. Measuring inconsistency in metaanalyses. BMJ Br Med J. 2003;327:557-
817 60.

818 54. Safarova MS, Satterfield BA, Fan X, Austin EE, Ye Z, Bastarache L, et al. A phenome-
819 wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR. NPJ Genom
820 Med. 2019;4:3.

821 55. Stoekenbroek RM, Lambert G, Cariou B, Hovingh GK. Inhibiting PCSK9 - biology
822 beyond LDL control. Nat Rev Endocrinol. 2018;15(1):52-62.

823 56. Lee S, Zhang C, Liu Z, Klevstig M, Mukhopadhyay B, Bergentall M, et al. Network
824 analyses identify liver-specific targets for treating liver diseases. Mol Syst Biol.
825 2017;13(8):938.

826 57. Marimuthu A, Subbannayya Y, Sahasrabuddhe NA, Balakrishnan L, Syed N, Sekhar
827 NR, et al. SILAC-based quantitative proteomic analysis of gastric cancer secretome.
828 Proteomics Clin Appl. 2013;7(5-6):355-66.

829 58. Dong B, Singh AB, Fung C, Kan K, Liu J. CETP inhibitors downregulate hepatic LDL
830 receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent
831 mechanism. Atherosclerosis. 2014;235(2):449-62.

832 59. Barter PJ, Cochran BJ, Rye KA. CETP inhibition, statins and diabetes. Atherosclerosis.
833 2018;278:143-6.

834 60. The Human Protein Atlas. PCKS9 2020 [Available from:
835 https://www.proteinatlas.org/ENSG00000169174-PCSK9/pathology.

836 61. The Human Protein Atlas. LDLR 2020 [Available from:
837 https://www.proteinatlas.org/ENSG00000130164-LDLR/pathology.

838 62. The Human Protein Atlas. LDLR Tissue 2020 [Available from:
839 https://www.proteinatlas.org/ENSG00000130164-LDLR/tissue.

840 63. Lee JS, Mukhopadhyay P, Matyas C, Trojnar E, Paloczi J, Yang YR, et al. PCSK9
841 inhibition as a novel therapeutic target for alcoholic liver disease. Scientific Reports.
842 2019;9(1):17167.

843 64. Lee JS, Rosoff D, Luo A, Longley M, Phillips M, Charlet K, et al. PCSK9 is Increased in
844 Cerebrospinal Fluid of Individuals With Alcohol Use Disorder. Alcoholism: Clinical and
845 Experimental Research. 2019;43(6):1163-9.

846 65. Wang K, Gerke TA, Chen X, Prosperi M. Association of statin use with risk of Gleason
847 score-specific prostate cancer: A hospital-based cohort study. Cancer Medicine.
848 2019;8(17):7399-407.

849 66. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, et al. Statins and
850 the risk of colorectal cancer. N Engl J Med. 2005;352(21):2184-92.

851 67. Khurana V, Bejjanki HR, Caldito G, Owens MW. Statins reduce the risk of lung cancer
852 in humans: a large case-control study of US veterans. Chest. 2007;131(5):1282-8.

853 68. Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A, et al. Statins
854 and prostate cancer risk: a case-control study. Am J Epidemiol. 2005;162(4):318-25.

855 69. Cholesterol Treatment Trialists C, Emberson JR, Kearney PM, Blackwell L, Newman C,
856 Reith C, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of
857 individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One.
858 2012;7(1):e29849.

859 70. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a
860 meta-analysis. JAMA. 2006;295(1):74-80.

861 71. Hernan MA, Sauer BC, Hernandez-Diaz S, Platt R, Shrier I. Specifying a target trial
862 prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin
863 Epidemiol. 2016;79:70-5.

864 72. Saka Herran C, Jane-Salas E, Estrugo Devesa A, Lopez-Lopez J. Protective effects of
865 metformin, statins and anti-inflammatory drugs on head and neck cancer: A systematic
866 review. Oral Oncol. 2018;85:68-81.

867 73. Dimitroulakos J, Marhin WH, Tokunaga J, Irish J, Gullane P, Penn LZ, et al. Microarray
868 and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas.
869 Neoplasia. 2002;4(4):337-46.

870 74. Osmak M. Statins and cancer: current and future prospects. Cancer Lett.
871 2012;324(1):1-12.

872 75. Gallagher EJ, LeRoith D. Obesity and Diabetes: The Increased Risk of Cancer and
873 Cancer-Related Mortality. Physiol Rev. 2015;95(3):727-48.

874 76. Joost HG. Diabetes and cancer: Epidemiology and potential mechanisms. Diabetes
875 Vasc Dis Re. 2014;11(6):390-4.

876 77. Hursting SD, DiGiovanni J, Dannenberg AJ, Azrad M, LeRoith D, Demark-Wahnefried
877 W, et al. Obesity, Energy Balance, and Cancer: New Opportunities for Prevention. Cancer
878 Prev Res. 2012;5(11):1260-72.

879 78. Bhat M, Skill N, Marcus V, Deschenes M, Tan X, Bouteaud J, et al. Decreased PCSK9
880 expression in human hepatocellular carcinoma. BMC Gastroenterol. 2015;15:176.
881

882 **Fig 1.** Forest plot showing the causal effects of *HMGCR*, *NPC1L1, CETP, PCSK9* and *LDLR*

883 variants on the oral and oropharyngeal cancer subsites in GAME-ON.

884

885



899

900

901 Effect estimates on oral and oropharyngeal cancer are reported on the log odds scale.



Effect estimates on oral and oropharyngeal cancer are reported on the log odds scale.

Fig 2. Forest plots showing the causal effects of cholesterol-lowering *PCSK9* and *LDLR* single nucleotide polymorphisms on coronary heart disease and combined oral/ oropharyngeal cancer in GAME-ON.



Effect estimates on oral and oropharyngeal cancer are reported on the log odds scale.

Fig 3. Scatter plots for *LDLR* and PCSK9 single nucleotide polymorphisms effect on combined oral/ oropharyngeal cancer in GAME-ON.



Fig 4. Forest plots showing inverse variance weighted meta-analysis effects of cholesterol-lowering *PCSK9* single nucleotide polymorphisms on head and neck cancer subsites .



Fig 5. Forest plots showing inverse variance weighted meta-analysis effects of cholesterol-lowering *LDLR* single nucleotide polymorphisms on head and neck cancer subsites